Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Pink or blue? The need for regulation is black and white.

Javitt GH.

Fertil Steril. 2006 Jul;86(1):13-5.

PMID:
16818030
2.

Prenatal genetic screening: the enigma of selective abortion.

Stoller D.

J Law Health. 1997-1998;12(1):121-40. No abstract available.

PMID:
10182027
3.

A warning that must not be ignored.

Hudson K.

New Sci. 2003 May 3;178(2393):5. No abstract available.

PMID:
14686409
4.

In search of a coherent framework: options for FDA oversight of genetic tests.

Javitt GH.

Food Drug Law J. 2007;62(4):617-52. No abstract available.

PMID:
18557224
5.

Test blunders risk needless abortions.

Concar D.

New Sci. 2003 May 3;178(2393):4-6. No abstract available.

PMID:
14686408
6.

Noninvasive prenatal diagnostic technology. Medical, market, or regulatory model?

Annas GJ.

Ann N Y Acad Sci. 1994 Sep 7;731:262-8. No abstract available.

PMID:
7944132
7.
8.

The wide, wild world of genetic testing.

Pollack A.

N Y Times Web. 2006 Sep 12:NYT4. No abstract available.

PMID:
16972376
9.

Putting DNA to the test.

[No authors listed]

Nature. 2009 Oct 8;461(7265):697-8. doi: 10.1038/461697b. No abstract available.

PMID:
19812626
10.

Europe to ban direct-to-consumer genetic tests?

Borry P.

Nat Biotechnol. 2008 Jul;26(7):736-7. doi: 10.1038/nbt0708-736. No abstract available.

PMID:
18612288
11.

Ethical aspects arising from non-invasive fetal diagnosis.

Newson AJ.

Semin Fetal Neonatal Med. 2008 Apr;13(2):103-8. doi: 10.1016/j.siny.2007.12.004. Review.

PMID:
18243828
12.

Genetic testing oversight.

Hudson KL.

Science. 2006 Sep 29;313(5795):1853. No abstract available.

13.

Towards quality assurance and harmonization of genetic testing services in the European Union.

Ibarreta D, Elles R, Cassiman JJ, Rodriguez-Cerezo E, Dequeker E.

Nat Biotechnol. 2004 Oct;22(10):1230-5. No abstract available.

PMID:
15470457
14.

Oversight of US genetic testing laboratories.

Hudson KL, Murphy JA, Kaufman DJ, Javitt GH, Katsanis SH, Scott J.

Nat Biotechnol. 2006 Sep;24(9):1083-90. No abstract available.

PMID:
16964214
15.

Non-invasive prenatal diagnosis for fetal sex determination: benefits and disadvantages from the service users' perspective.

Lewis C, Hill M, Skirton H, Chitty LS.

Eur J Hum Genet. 2012 Nov;20(11):1127-33. doi: 10.1038/ejhg.2012.50. Epub 2012 Mar 28.

16.

Screening: the bigger picture.

Gibson L.

Nurs Stand. 2007 Mar 14-20;21(27):22-3.

PMID:
17390941
17.

Regulators weigh risks of consumer genetic tests.

Schmidt C.

Nat Biotechnol. 2008 Feb;26(2):145-6. doi: 10.1038/nbt0208-145. No abstract available.

PMID:
18259159
18.

Non-invasive fetal RHD genotyping tests: a systematic review of the quality of reporting of diagnostic accuracy in published studies.

Freeman K, Szczepura A, Osipenko L.

Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):91-8. doi: 10.1016/j.ejogrb.2008.10.010. Epub 2008 Dec 9. Review.

PMID:
19081172
19.

Troubling times for embryo gene tests.

Hutson S.

New Sci. 2006 Mar 18-24;189(2543):14-5. No abstract available.

PMID:
16832958
20.

Regulatory agency consideration of pharmacogenomics.

Pendergast MK.

Exp Biol Med (Maywood). 2008 Dec;233(12):1498-503. doi: 10.3181/0806-S-207. Epub 2008 Oct 10. Review.

PMID:
18849547

Supplemental Content

Support Center